Axonics stock joins Boston Scientific after USD 3.7 billion deal
Published on 09/30/2026 at 08:43 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
Axonics stock joined Boston Scientific after the medical-device company completed its acquisition on November 15, 2024. The transaction gave Axonics shareholders USD 71.00 per share and moved the sacral neuromodulation business into Boston Scientific's urology division.
USD 3.7 billion deal reshaped Axonics
According to Asset News 4U, Boston Scientific completed the purchase of 100 percent of Axonics on November 15, 2024. The filing-based account states that the upfront payment was USD 71.00 per share, or approximately USD 3.409 billion net of cash acquired.
A separate September 2026 market report put the deal value at USD 3.7 billion, highlighting the strategic value of Axonics' rechargeable systems for overactive bladder and bowel dysfunction. The acquisition therefore marked a transition from a standalone Nasdaq issuer to an operating business within a larger medical-technology platform.
Former CEO returns to medtech
The latest dated reference to Axonics came on September 24, 2026. Business Wire reported that Raymond W. Cohen, Axonics' co-founder and former CEO, became chairman of CAIRDAC, a developer of leadless cardiac-pacing technology.
The same release said Axonics generated more than USD 1.2 billion in revenue during the four years after commercial launch. That figure places the company's growth record in context, while its 2018 initial public offering shows how quickly the business moved from public-market debut to acquisition.
Axonics' business now sits inside Boston Scientific
StockTitan described Axonics on September 24, 2026, as a global implantable-neuromodulation company and confirmed the late-2024 acquisition by Boston Scientific. Its profile identifies the former ticker as AXNX and the primary listing as Nasdaq.
For readers searching for Axonics stock, the key reference is therefore corporate history rather than a new standalone earnings cycle. The commercial assets remain relevant through Boston Scientific's urology portfolio, but the transaction terms and integration date define the security's current status.
Acquisition date defines AXNX status
Axonics stock is tied to the November 15, 2024 completion date and the USD 71.00 per-share consideration, while the broader transaction was reported at USD 3.7 billion. The company operated in medical devices and sacral neuromodulation, with products aimed at urinary and bowel dysfunction.
Axonics company profile
- Company: Axonics, Inc.
- ISIN: US05465P1012
- Ticker: AXNX
- Primary exchange: Nasdaq
- Sector / Industry: Healthcare / Medical devices
